Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy.
Bragadóttir
G
G
Department of Laboratory Haematology and Haemostasis Center, Landspitali University Hospital, 101 Reykjavik, Iceland.
Onundarson
P T
PT
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007592:Joint Diseases / Q000188:drug therapy*; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases